The League against cancer denounces the exorbitant prices of treatments. Glivec, 37,000 euros per year, Sovaldi, 41,000 euros or the Keytruda, soon to be sold
News And Worlds
The League against cancer denounces the exorbitant prices of treatments. Glivec, 37,000 euros per year, Sovaldi, 41,000 euros or the Keytruda, soon to be sold